This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Woollen, B.H. Articles by Dollery, C.T. Search for Related Content PubMed PubMed Citation Articles by Woollen, B.H. Articles by Dollery, C.T. Social Bookmarking                         What's this?

Oral Pharmacokinetics of Fluazifop-Butyl in Human Volunteers

ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, SK10 4TJ

T.B. Hart

ICI Agrochemicals, Fernhurst, Sussex, UK

P.L. Batten

ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, SK10 4TJ

W.J.D. Laird

ICI Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, SK10 4TJ

D.S. Davies

Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK

C.T. Dollery

Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 ONN, UK

1 Fluazifop-butyl, the active ingredient of FUSILADE, a selective herbicide, was administered orally to three male volunteers at a dose level of 0.07 mg kg^-1 body weight. Over a period of 6 d between 80 and 93% of the dose was excreted in urine as the metabolite fluazifop, the majority within the first 24 h. Peak plasma concentrations of fluazifop occurred 1-2.5 h after administration.

2 The elimination of fluazifop from plasma and urine can be described by a one-compartment pharmacokinetic model and the elimination half-life was estimated from blood and urine data to be within the range 9-37 h. Fluazifop was found to bind to serum proteins.

3 The study indicates that the amount of fluazifop-butyl absorbed in exposed persons can be assessed by measuring fluazifop concentrations in urine.

Human & Experimental Toxicology, Vol. 10, No. 1, 39-43 (1991)
DOI: 10.1177/096032719101000107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T.R. Auton, D.R. Westhead, B.H. Woollen, R.C. Scott, and M.F. Wilks A Physiologically Based Mathematical Model of Dermal Absorption in Man Human and Experimental Toxicology, January 1, 1994; 13(1): 51 - 60. [Abstract] [PDF]

				J. M. Rawlings, W. McLean Provan, M. F. Wilks, and P. L. Batten Comparison of Two Methods for Determining the Toxicokinetics of Fluazifop-butyl after Intravenous Dosing in Rats Human and Experimental Toxicology, January 1, 1994; 13(2): 123 - 129. [Abstract] [PDF]

				T.R. Auton, J.D. Ramsey, and B.H. Woollen Modelling Dermal Pharmacokinetics Using in vitro Data. Part II. Fluazifop-butyl in Man Human and Experimental Toxicology, January 1, 1993; 12(3): 207 - 213. [Abstract] [PDF]

				J.D. Ramsey, B.H. Woollen, T.R. Auton, P.L. Batten, and J.E. Leeser Pharmacokinetics of Fluazifop-butyl in Human Volunteers II: Dermal Dosing Human and Experimental Toxicology, January 1, 1992; 11(4): 247 - 254. [Abstract] [PDF]